Last reviewed · How we verify
AMG531
AMG531 is a thrombopoietin receptor agonist.
AMG531 is a thrombopoietin receptor agonist. Used for Thrombocytopenia.
At a glance
| Generic name | AMG531 |
|---|---|
| Sponsor | Kyowa Kirin Korea Co., Ltd. |
| Drug class | Thrombopoietin receptor agonist |
| Target | Thrombopoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
It works by stimulating the thrombopoietin receptor, which leads to increased platelet production. This can be beneficial for patients with thrombocytopenia or other platelet-related disorders.
Approved indications
- Thrombocytopenia
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- Single Arm Romiplostim to Prevent CIT (EARLY_PHASE1)
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (PHASE2)
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (PHASE3)
- Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA (PHASE2)
- Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy (PHASE2)
- Romiplostim N01 for Platelet Recovery After Haploidentical HSCT (PHASE1)
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG531 CI brief — competitive landscape report
- AMG531 updates RSS · CI watch RSS
- Kyowa Kirin Korea Co., Ltd. portfolio CI